Abiomed Concerns Deemed Overblown and 4 Stock Analyses to Track

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Abiomed Inc. (NASDAQ:ABMD): Wunderlich said history shows that categories on the CMS list usually do not advance to the National Coverage Determination, or NCD, review stage. The firm believes concern of a possible NCD for Abiomed Inc.’s Impella are overblown and reiterates a Buy rating on the stock.

OSI Systems, Inc. (NASDAQ:OSIS): Benchmark Co. viewed the recent pullback in shares of OSI Systems, Inc. as a buying opportunity. The firm anticipates the business impact to OSI from the allegation of body scanner test data manipulation to be limited and reiterates a Buy rating on the stock.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Hercules Offshore, Inc. (NASDAQ:HERO): Deutsche Bank viewed Hercules Offshore, Inc.’s announcement as positive in their latest fleet status report saying that they reactivated a cold stacked rig with a 35-day contract. The firm called the stock their favorite small cap and keeps a Buy rating on the name with an $8 price target.

Tractor Supply Company (NASDAQ:TSCO) was added to the Conviction Buy List and Sherwin-Williams was removed from Nomura.

Broadcom Corp. (NASDAQ:BRCM): Citigroup expects Broadcom Corp. to raise their fourth quarter guidance for analyst day on December 6. They believe that strong iPhone sales are driving higher Wi-Fi revenue and they keep a Buy rating on Broadcom with a $41 price target. Conversely, Citi anticipates a risk to Intel’s (NASDAQ:INTC) fourth quarter guidance and lowered their price target for the stock from $23 to $21. Citi keeps a Neutral rating on Intel.

Investing Insights: Is Cisco’s Stock A Good Buy Right Now?


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business